FindTrial
Sign In

ONCE WEEKLY DOSING OF DARBEPOETIN ALPHA AS PROPHYLACTIC TREATMENT FOR ANEMIA IN ELDERLY CANCER PATIENTS

ONCE WEEKLY DOSING OF DARBEPOETIN ALPHA AS PROPHYLACTIC TREATMENT FOR ANEMIA IN ELDERLY CANCER PATIENTS

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2005-003701-91-IT
Enrollment
Unknown
Registered
2007-04-04
Start date
2004-09-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

ELDERLY PATIENTS WITH GASTROINTESTINAL AND LUNG CANCER MedDRA version: 6.1 Level: SOC Classification code 10029104

Interventions

Trade Name: ARANESP SC EV 1SIR 150MCG 0,3M Pharmaceutical Form: Solution for injection Current Sponsor code: B03XA02 DERBEPOETIN ALFA Concentration unit: µg microgram(s) Concentration type: equal Conc

Sponsors

ISTITUTO NAZIONALE PER LA CURA TUMORI
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026